Pallis A G, Mouzas I A
Gastroenterology Department, University Hospital of Heraklion, Heraklion, Greece.
Anticancer Res. 2006 Nov-Dec;26(6C):4809-15.
Surgery remains the only curative therapy for colon cancer. However, several studies during the last years have proved that systemic chemotherapy in the adjuvant setting definitely improves the curative rate for those patients with localized colon cancer. The combination of 5-fluorouracil (5-FU) and leukovorin (LV) remained the reference treatment for over a decade. However, oxaliplatin-based chemotherapy has emerged as the new standard of care in adjuvant treatment of stage III colon cancer. The role of adjuvant therapy in stage II cancers remains controversial and its routine use is recommended only in high risk patients. This review focuses on the efficacy, safety and toxicity of several drugs used in the adjuvant treatment of colon cancer and on clinical issues, such as the timing for initiation of chemotherapy, its duration and treatment of special patient subgroups, such as stage II or elderly patients.
手术仍然是结肠癌唯一的治愈性疗法。然而,过去几年的多项研究证明,辅助治疗中的全身化疗确实提高了局限性结肠癌患者的治愈率。5-氟尿嘧啶(5-FU)和亚叶酸钙(LV)联合用药十多年来一直是参照治疗方案。然而,基于奥沙利铂的化疗已成为III期结肠癌辅助治疗的新护理标准。辅助治疗在II期癌症中的作用仍存在争议,仅建议在高危患者中常规使用。本综述重点关注用于结肠癌辅助治疗的几种药物的疗效、安全性和毒性,以及临床问题,如化疗开始时间、疗程,以及特殊患者亚组(如II期患者或老年患者)的治疗。